Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07005947 · ClinicalTrials.gov registry record
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
A clinical trial of Long COVID-19 and Diabetic Neuropathy, sponsored by CND Life Sciences.
- Active
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT07005947 is a study of Long COVID-19 and Diabetic Neuropathy that is active but no longer recruiting, run by CND Life Sciences. The registered enrollment target is 300 participants, roughly in line with the 283-participant average among 10 other Long COVID-19 trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT07005947, a study of Long COVID-19 and Diabetic Neuropathy, is active but no longer recruiting, sponsored by CND Life Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.
Conditions Studied
Study Locations (1)
Arizona
- CND Life Sciences - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2026-04-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07005947
The ClinicalTrials.gov registry entry for NCT07005947 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 283-participant average among 10 other Long COVID-19 trials with a reported enrollment target. The listed sponsor is CND Life Sciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Long COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT07005947 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT07005947 about?
NCT07005947 is a clinical study titled "Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project". This is a prospective, longitudinal study involving 300 participants for a single visit to compare Long COVID-19 neurocutaneous biosignatures with those of other disorders affecting the sensory and autonomic nervous system.
What is the current status of trial NCT07005947?
This trial is currently active not recruiting. The enrollment target is 300 participants. The study started on 2023-11-30. Estimated completion is 2026-04-16.
What conditions does trial NCT07005947 study?
This clinical trial studies the following conditions: Long COVID-19, Diabetic Neuropathy, Postural Orthostatic Tachycardia Syndrome (POTS), Acute COVID-19.
Who is sponsoring clinical trial NCT07005947?
This trial is sponsored by CND Life Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07005947 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
RECRUITING · Phase 3
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
RECRUITING · Phase 2
-
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
ACTIVE NOT RECRUITING · Phase 2
-
RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
ACTIVE NOT RECRUITING · Phase 2
-
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.